This content is from: Patents

Is an injunction available in biosimilar cases under state law?

The US Supreme Court in Sandoz v Amgen remanded the question of whether an injunction is available to Amgen under state unfair competition laws. Natalie Rahhal analyses how the Federal Circuit may rule

To access our in-house intelligence please request a trial here.

Read this article – and more – for a one-week period.

REQUEST ACCESS

Are you already an Managing IP subscriber? Login here

Related

Instant access to all of our content. Membership Options | One Week Trial